CFDA Announces the Normative Documents to be Amended and Abolished for the Reform of Streamlining Administration, Delegating Powers and Improving Regulation and Services
Recently, the China Food and Drug Administration ("CFDA") has issued the Announcement of the Results of Sorting Out Normative Documents Involved in the Reform of Streamlining Administration, Delegating Powers, and Improving Regulation and Services (the "Announcement").
Two normative documents are amended and another seven ones are repealed, according to the Announcement. In particular, details about two updated documents are as follows. First, the Item 9, previously referring to the "financial balance sheets issued by an accounting firm", in the Appendix II, the Application Materials Required for Becoming a National (Regional) Wholesale Enterprise, affixed to the Circular on Issuing the Administrative Measures for Business Operations in Narcotic Drugs and Psychotropic Drugs (for Trial Implementation), is now revised to read as the "financial balance sheets". Second, the "organization code", as set out in the Appendix I, the Application Form for Filing a Project for the Experimental Studies of Narcotic Drugs or Psychotropic Drugs, affixed to the Circular on the Provisions for the Administration of Experimental Studies of Narcotic Drugs and Psychotropic Drugs, is removed. At the same time, another seven documents, including the "Circular on Launching Programs to Overhaul Traditional Chinese Medicine Healthcare Products", are annulled.